Ideaya Biosciences, Inc.

South San Francisco, CA · Founded 2015 · CIK 0001676725 · Biotech · Private

Precision oncology therapeutics targeting specific cancer vulnerabilities through small molecule and biological drugs

ideayabio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$111M
2 Form D · May 2018
101 months since last filing
Contracts
—
No federal contracts on record
Patents
40
14 granted · 26 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$17,360,532
Private capital raisedForm D · SEC$94,019,988
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1513SYNCANICA BIO——
1514Juvenescence—$115M
1515REPLICEL LIFE SCIENCES INC.—$5.8M
1516Ideaya Biosciences, Inc.—$111M
1517Virscio Inc——
1518Moonwalk Biosciences—$110M
1519DEGROME THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Brian DanielsDirector
  • John DiekmanDirector
  • Michael DillonExecutive Officer
  • Jeffrey HagerExecutive Officer
  • Yujiro HataDirector · Executive Officer
  • Edward HuDirector
  • Terry RosenDirector
  • Thilo SchroederDirector
  • Timothy ShannonDirector
  • Tim SmithExecutive Officer
  • Jeffrey SteinDirector
  • Paul StoneExecutive Officer

Patents

USPTO · 14 granted of 40
  • Treatment Of Er+ Breast Cancer Comprising Homologous Recombination Deficiency Using Parg Inhibitorapplication
  • 2-OXOQUINAZOLINE Derivatives As Methionine Adenosyltransferase 2A Inhibitorsapplication
  • Atropisomers Of MAT2A Inhibitorsapplication
  • 2-OXOQUINAZOLINE Crystalline Formsapplication
  • Cancer Treatments Using Mta-cooperative PRMT5 Inhibitors And MAT2A Inhibitorsapplication
  • Thiadiazolyl Derivativesapplication
  • Thiadiazolyl Derivativesgranted
  • 2-OXOQUINAZOLINE Derivatives As Methionine Adenosyltransferase 2A Inhibitorsgranted
  • Piperazine Substituted Indazole Compounds As Inhibitors Of Pargapplication
  • Thiadiazolyl Derivatives As Dna Polymerase Theta Inhibitors And Uses Thereofapplication
  • Thiadiazolyl Derivatives As Dna Polymerase Theta Inhibitors And Uses Thereofapplication
  • Thiadiazolyl Derivatives As Dna Polymerase Theta Inhibitors And Uses Thereofgranted

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.